{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:06:34Z","timestamp":1777493194033,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of this study was to test the efficacy and safety of olanzapine\u2009+\u2009topiramate versus olanzapine monotherapy in the treatment of bipolar disorder (BPD) and treatment-attendant weight gain in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>\n                      Subjects (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u200940) were outpatients of both sexes, 6\u201317 years of age, with a\n                      <jats:italic toggle=\"yes\">Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>\n                      , 4\n                      <jats:sup>th<\/jats:sup>\n                      edition (DSM-IV) diagnosis of BPD (manic, hypomanic, or mixed) and Young Mania Rating Scale (YMRS) total score of &gt;15 treated over 8-week periods in two partially concurrent open-label trials with olanzapine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200917) or olanzapine\u2009+\u2009topiramate (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200923).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Subjects in both groups experienced a statistically significant reduction in YMRS scores after 8-week, open-label treatment with olanzapine (baseline YMRS\u2009=\u200926.7\u2009\u00b1\u20099.5; end-point YMRS\u2009=\u200918.2\u2009\u00b1\u200912.5,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.04) and olanzapine\u2009+topiramate (baseline YMRS\u2009=\u200931.3\u2009\u00b1\u20097.9; end-point YMRS\u2009=\u200920.4\u2009\u00b1\u200911.4,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.04). There was no difference in response between the two groups based on YMRS or Clinical Global Impressions\u2013Improvement (CGI-I) scores. Adverse events were few and mild and similar between the two groups, with the exception of weight gain. The weight gain in the olanzapine group was 5.3\u2009\u00b1\u20092.1\u2009kg and the weight gain in the olanzapine\u2009+\u2009topiramate group was statistically significantly lower, 2.6\u2009\u00b1\u20093.6\u2009kg.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Augmentation of olanzapine with topiramate resulted in a reduced weight gain over the course of an 8-week, open-label trial when compared with olanzapine treatment alone, but did not lead to greater reduction in symptoms of mania.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2009.0042","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T18:59:33Z","timestamp":1256929173000},"page":"539-545","source":"Crossref","is-referenced-by-count":50,"title":["Comparison of Open-Label, 8-Week Trials of Olanzapine Monotherapy and Topiramate Augmentation of Olanzapine for the Treatment of Pediatric Bipolar Disorder"],"prefix":"10.1177","volume":"19","author":[{"given":"Janet","family":"Wozniak","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mick","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Waxmonsky","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Kotarski","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liisa","family":"Hantsoo","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Biederman","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.6.967-a"},{"key":"e_1_3_2_4_1","volume-title":"Comparative efficacy of atypical antipsychotics for pediatric bipolar disorder","author":"Biederman J","year":"2005","unstructured":"Biederman J. Comparative efficacy of atypical antipsychotics for pediatric bipolar disorder. 158th Annual meeting of the American Psyciatric Association, Atlanta, GA. American Psychiatric Association, 2005."},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900019489"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.03.019"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.311"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200106000-00015"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00337-8"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.1999.10111.x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2001.30501.x"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80061-3"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000220851.94392.30"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454602762599862"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00011"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000159151.75345.20"},{"key":"e_1_3_2_17_1","first-page":"198","article-title":"Clozapine weight gain, plus topiramate weight loss","volume":"45","author":"Dursun SM","year":"2000","unstructured":"Dursun SM, , Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry, 45:198. 2000.","journal-title":"Can J Psychiatry"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830230069010"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199908000-00011"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595568"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10401230109147382"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.6.968a"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200211000-00017"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0610"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.13.3.384"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200109000-00008"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970701268864"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00110-4"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00961-6"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00488.x"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0401"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(01)00562-4"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200212000-00010"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.2.247"},{"issue":"8","key":"e_1_3_2_36_1","first-page":"118S","article-title":"Olanzapine in the treatment of acute mania in adolescents with bipolar I disorder: A 3-week randomized double-blind placebo-controlled study","volume":"59","author":"Tohen M","year":"2006","unstructured":"Tohen M, , Kryzhanovskaya L, , Carlson GA, , DelBello M, , Wozniak J, , Kowatch R, , Wagner K, , Findling RL, , Lin D, , Robertson-Plouch C, , Xu W, , Huang X, , Dittmann R, , Blederman J. Olanzapine in the treatment of acute mania in adolescents with bipolar I disorder: A 3-week randomized double-blind placebo-controlled study. Biol Psychiatry, 59,8S:118S. 2006b.","journal-title":"Biol Psychiatry"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111932"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0024"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.08.004"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0504"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1207\/S15374424JCCP3104_15"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2009.0042","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2009.0042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2009.0042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:54:38Z","timestamp":1777388078000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2009.0042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1089\/cap.2009.0042"],"URL":"https:\/\/doi.org\/10.1089\/cap.2009.0042","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}